Kyverna Therapeutics (KYTX) Assets Average (2024 - 2026)

Kyverna Therapeutics (KYTX) has 3 years of Assets Average data on file, last reported at $275.4 million in Q1 2026.

• Quarterly Assets Average fell 2.56% year-over-year to $275.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $275.4 million (down 2.56% YoY) and the FY2025 annual result came in at $299.2 million, up 57.56% from the prior year.
• Assets Average grew to $275.4 million in Q1 2026, from $240.5 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $376.6 million in Q2 2024 to a low of $206.8 million in Q3 2025.
• A 3-year average of $281.2 million and a median of $275.4 million in 2026 frame the typical range for Assets Average.
• The widest YoY moves for Assets Average: up 21.52% in 2025, down 41.1% in 2025.
• Tracing KYTX's Assets Average over 3 years: stood at $321.9 million in 2024, then dropped by 25.29% to $240.5 million in 2025, then advanced by 14.53% to $275.4 million in 2026.
• The last three Assets Average figures came in at $275.4 million (Q1 2026), $240.5 million (Q4 2025), and $206.8 million (Q3 2025), per Business Quant data.